Leerink Partnrs Comments on Aurinia Pharmaceuticals Inc.’s Q4 2024 Earnings (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Leerink Partnrs upped their Q4 2024 EPS estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Thursday, May 2nd. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is ($0.06) per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ FY2025 earnings at $0.23 EPS.

Several other research firms have also commented on AUPH. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, March 1st. StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Cantor Fitzgerald decreased their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Jefferies Financial Group dropped their price objective on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a research report on Friday, February 16th. Finally, Royal Bank of Canada decreased their target price on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ AUPH opened at $5.12 on Monday. Aurinia Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $12.43. The stock’s fifty day moving average is $5.16 and its 200 day moving average is $7.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.05 and a current ratio of 5.60. The stock has a market capitalization of $732.26 million, a P/E ratio of -11.91 and a beta of 1.36.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The company had revenue of $45.10 million for the quarter, compared to analyst estimates of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. The company’s quarterly revenue was up 58.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.18) EPS.

Institutional Trading of Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC grew its stake in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after acquiring an additional 3,488,000 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 39.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock worth $18,416,000 after purchasing an additional 576,120 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $2,089,000. GSA Capital Partners LLP increased its stake in Aurinia Pharmaceuticals by 196.1% during the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after purchasing an additional 231,260 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in Aurinia Pharmaceuticals by 154.3% during the third quarter. Sunbelt Securities Inc. now owns 196,090 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 118,990 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.